Vyome Holdings, Inc. — 2017 Q3 10-Q Summary
Important filing-identity discrepancy: The supplied metadata identifies Vyome Holdings, Inc., but the filing itself is for Obalon Therapeutics, Inc. The financial information below summarizes the filing as provided and should not be attributed to Vyome without verification.
Business context and reporting period
This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2017. Obalon was a medical-device company commercializing its FDA-approved swallowable intragastric balloon system for weight loss. U.S. sales began in January 2017; prior-period sales were outside the United States. The company was investing in U.S. commercialization, manufacturing capacity, and product development.
Key financial metrics
| Metric | Three months ended Sep. 30, 2017 | Nine months ended Sep. 30, 2017 |
|---|---|---|
| Revenue | $2.787 million | $6.222 million |
| Gross profit / gross margin | $1.473 million / 53% | $3.095 million / 50% |
| Research and development | $2.798 million | $7.958 million |
| Selling, general and administrative | $7.813 million | $19.606 million |
| Operating loss | $9.138 million | $24.469 million |
| Net loss | $9.170 million | $24.645 million |
| Basic and diluted loss per share | $0.55 | $1.48 |
For the nine months, operating cash use was $21.427 million; investing cash use was $39.721 million, primarily reflecting purchases of short-term investments; and financing provided $0.256 million. Cash and cash equivalents declined to $12.083 million from $72.975 million at December 31, 2016, while short-term investments rose to $41.289 million. Combined cash and short-term investments were $53.372 million.
At September 30, 2017, total assets were $59.078 million, total liabilities $15.562 million, and stockholders’ equity $43.516 million. Term debt had a $10.0 million face value ($9.912 million net of issuance costs), including $0.957 million classified as current. The loan bears interest at the greater of prime plus 1.5% or 5.0%; an additional $5.0 million tranche was available through December 21, 2017. The company reported an accumulated deficit of $101.254 million.
Material changes versus the prior comparable period
- Third-quarter revenue increased to $2.787 million from $0.773 million; nine-month revenue increased to $6.222 million from $2.621 million. Management attributed growth to higher unit volume and selling prices. Most 2017 sales were to U.S. physicians and institutions; all 2016 sales were to the Middle East distributor.
- Gross margin improved to 53% from 17% for the quarter and to 50% from 26% for the nine-month period, which management attributed to higher average selling prices and fixed manufacturing overhead spread over more units.
- Quarterly and nine-month net losses widened to $9.170 million and $24.645 million, respectively, from $5.260 million and $12.972 million. SG&A rose substantially as the company expanded its sales and marketing organization and incurred public-company costs.
- SG&A included $1.398 million of non-cash expense for shares issued to settle Polyzen patent litigation. Stock-based compensation for the nine months increased to $2.102 million from $0.200 million.
- Cash and cash equivalents fell materially, but the company held $41.289 million in short-term U.S. Treasury investments at quarter-end. Nine-month operating cash use increased from $13.593 million to $21.427 million.
Outlook, risks, contingencies, and unusual items
- Management said existing cash, short-term investments, and expected revenue were expected to fund operations for at least 12 months from the filing date. It also expected continued losses and higher costs for U.S. commercialization, sales and marketing, manufacturing expansion, R&D, and clinical work. No specific revenue or profitability guidance was provided.
- The company described the U.S. intragastric-balloon market as small and immature, with limited market penetration and uncertain physician and patient adoption. It cited manufacturing scale-up challenges and dependence on single-source suppliers for key components.
- All revenue was from the Obalon balloon system. Bader, the Middle East distributor, represented 28% of third-quarter revenue and 13% of nine-month revenue; it accounted for 20% of quarter-end accounts receivable. The filing also identifies Bader as the only customer exceeding 10% of revenue in the periods presented.
- Obalon submitted PMA supplements for its navigation system and next-generation Touch inflation system; FDA approval was not assured, and additional testing could be required. The filing also notes FDA safety communications about deaths involving other companies’ saline-filled balloons, which could affect perceptions of the broader category.
- Polyzen litigation was settled in August 2017 for 150,000 common shares and a general release; the company recorded $1.398 million in non-cash expense. After quarter-end, Obalon agreed to issue 25,000 shares and make a nominal cash payment to settle Phagia contractual claims.
- The term loan is secured by substantially all assets other than intellectual property and includes operating restrictions. The company warned that future financing might be unavailable or dilutive and that commercialization, regulatory, product-safety, competition, and liquidity risks could adversely affect results.
- Management concluded disclosure controls were effective at a reasonable-assurance level and reported no material changes in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Confirm the registrant identity: the supplied filing is for Obalon Therapeutics, Inc., not Vyome Holdings, Inc.
- Assess whether U.S. sales growth and improved gross margins can continue as commercialization scales, and compare actual sales with the company’s rising operating expenses and cash burn.
- Track liquidity and debt, including the availability and terms of the additional $5.0 million loan tranche, loan covenants, and management’s stated 12-month funding outlook.
- Monitor customer concentration and collection of Bader’s $0.5 million receivable, as well as the company’s reliance on its single-product business.
- Check FDA decisions and any required additional testing for the navigation and Touch systems, and review post-approval safety data, manufacturing capacity, and reported adverse events.
- Confirm settlement share issuances and related expenses, including the post-quarter Phagia settlement, and review subsequent filings for further legal or financing developments.